PEPTIDEATLAS / LIBRARY
What is MariTide? MARITIME Phase 3 and status
MariTide (maridebart cafraglutide): mechanism, the MARITIME Phase 3 programme and the limits of current evidence.
Mechanism and research context
An antibody-peptide conjugate studied in the MARITIME programme. Amgen describes MariTide as an investigational molecule in Phase 3; a clinical programme is not regulatory approval.
Continue reading
How to assess the evidence
Check the trial, participant population, duration and comparison. Consider adverse events and discontinuations alongside the measured effect.
Results for a combination do not automatically apply to either component alone. Separate trials are not a head-to-head comparison.
What the results do not establish
Clinical findings do not establish the composition or quality of an online shop product. This profile provides no individual treatment, dosing or use instructions.
Primary source checked: 2026-09-22. Not presented as independently medically reviewed.